FENACLON

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H14ClNO
Molecular Weight	211.688
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClCCC(=O)NCCC1=CC=CC=C1

InChI

InChIKey=BITWVVLBVUMFHU-UHFFFAOYSA-N

InChI=1S/C11H14ClNO/c12-8-6-11(14)13-9-7-10-4-2-1-3-5-10/h1-5H,6-9H2,(H,13,14)

HIDE SMILES / InChI

Molecular Formula	C11H14ClNO
Molecular Weight	211.688
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14303595 | http://www.etolen.com/index.php?option=com_content&view=article&id=2981:%D1%84%D0%B5%D0%BD%D0%B0%D0%BA%D0%BE%D0%BD&catid=9&Itemid=101 | https://www.ncbi.nlm.nih.gov/pubmed/5597736

Fenaclon is an anticonvulsant. It was developed in the former USSR. It is indicated for the treatment of epilepsy.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
acetylcholine metabolic process 11 Target ID: GO:0008291 Sources: https://www.ncbi.nlm.nih.gov/pubmed/5599516	Modulator 846

Conditions

Condition	Modality	Targets	Highest Phase	Product
Epilepsy 121 Sources: https://www.ncbi.nlm.nih.gov/pubmed/5748835 https://www.ncbi.nlm.nih.gov/pubmed/14303595 https://www.ncbi.nlm.nih.gov/pubmed/14245997	Primary		Approved 8583	Phenacon Approved Use Fenaclon is indicated for the treatment of epilepsy. Launch Date 1957

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2C19 2057

Drug as perpetrator

Target	Modality	Activity
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/9376#section=Biological-Test-Results Page: 4.0	inconclusive [IC50 30.9008 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/9376#section=Biological-Test-Results Page: 59.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/9376#section=Biological-Test-Results Page: 60.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/9376#section=Biological-Test-Results Page: 56.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/9376#section=Biological-Test-Results Page: 53.0	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/9376#section=Biological-Test-Results Page: 60.0

PubMed

Title	Date	PubMed
[Effect of phenacon on the content of acetylcholine and the activity of cholinesterase in the brain in electroshock].	1967-03-01	5599516
[Effect of phenacon on the content of potassium and sodium ions and of acetylcholine in the brain].	1965-01-01	5845035
[THE ANTIEPILEPTIC PREPARATION PHENACON].	1964-10	14303595

Patents

Sample Use Guides

In Vivo Use Guide

1-2 g after the meal, 2–5 g per day

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:04:48 GMT 2025` Edited by `admin` on `Mon Mar 31 18:04:48 GMT 2025`
Record UNII	6M4IR9QY13
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FENACLON

Official Name

English

fenaclon [INN]

Preferred Name

English

3-CHLORO-N-PHENETHYLPROPIONAMIDE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C264